Related Experiment Video

Updated: Mar 18, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

4.5K

Efficacy and safety of caspofungin in children: systematic review and meta-analysis

María T Rosanova1, David Bes2, Pedro Serrano Aguilar3

  • 1Servicio de Control Epidemiológico e Infectología, Hospital J. P. Garrahan, Ciudad Autónoma de Buenos Aires, Argentina. margris2@yahoo.com.ar.

Archivos Argentinos De Pediatria
|July 12, 2016
PubMed
Abstract

Insights

Caspofungin shows promise as an alternative antifungal for children with invasive fungal infections. However, more research is needed to confirm its efficacy and safety compared to standard treatments.

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacology
  • Mycology

Background:

  • Invasive fungal infections pose significant risks in pediatric populations.
  • Caspofungin, an echinocandin, is an alternative treatment option for pediatric fungal infections.
  • Limited evidence exists on caspofungin's efficacy and safety in children compared to standard therapies.

Purpose of the Study:

  • To assess the efficacy and safety of caspofungin versus other antifungals in pediatric invasive fungal infections.
  • To review existing evidence on caspofungin for pediatric antifungal prevention and treatment.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs).
  • Inclusion criteria: Jadad scale score >3, studies on caspofungin, patients aged 0-18 years.
  • Search strategy focused on identifying high-quality evidence.

Main Results:

  • The search aimed to identify methodologically sound RCTs on caspofungin in children.
  • Identified studies focused on caspofungin use in pediatric patients aged 0-18 years.
  • Methodological quality assessed using the Jadad scale.

Conclusions:

  • Caspofungin may be a viable alternative for pediatric invasive fungal infections.
  • The current evidence base is limited due to a small number of publications.
  • Further research is necessary to establish definitive conclusions on caspofungin's role in pediatric antifungal therapy.
Keywords:
CaspofunginChildEfficacyMycosisSafety

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

14.3K
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

11.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
645
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
360
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
423
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
60
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
692